Technical Analysis for ATXI - Avenue Therapeutics, Inc.

Grade Last Price % Change Price Change
F 3.40 -2.86% -0.10
ATXI closed down 2.86 percent on Monday, July 1, 2024, on 29 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Fell Below 20 DMA Bearish -2.86%
Bollinger Band Squeeze Range Contraction -2.86%
Outside Day Range Expansion -2.86%
20 DMA Support Bullish -5.03%
Bollinger Band Squeeze Range Contraction -5.03%
NR7 Range Contraction -5.03%

   Recent Intraday Alerts

Alert Time
20 DMA Resistance about 9 hours ago
10 DMA Resistance about 9 hours ago
Fell Below Previous Day's Low about 9 hours ago
Down 2 % about 9 hours ago
Down 1% about 9 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Avenue Therapeutics, Inc. Description

Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Tramadol is also combined with acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDS) in clinical practice. During the year ending December 31, 2016, the Company had completed a pharmacokinetics (PK) study for IV Tramadol in healthy volunteers.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Drugs Chemical Compounds Chloride Opioids Analgesics Amines Neurochemistry Hepatotoxins Pharmacokinetics Paracetamol Nonsteroidal Anti Inflammatory Drug

Is ATXI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 93.75
52 Week Low 3.25
Average Volume 76,088
200-Day Moving Average 16.00
50-Day Moving Average 4.39
20-Day Moving Average 3.56
10-Day Moving Average 3.54
Average True Range 0.35
RSI (14) 38.27
ADX 10.83
+DI 14.92
-DI 15.00
Chandelier Exit (Long, 3 ATRs) 2.93
Chandelier Exit (Short, 3 ATRs) 4.30
Upper Bollinger Bands 3.84
Lower Bollinger Band 3.27
Percent B (%b) 0.23
BandWidth 15.93
MACD Line -0.28
MACD Signal Line -0.38
MACD Histogram 0.1001
Fundamentals Value
Market Cap 126.84 Million
Num Shares 37.3 Million
EPS -2.62
Price-to-Earnings (P/E) Ratio -1.30
Price-to-Sales 0.00
Price-to-Book 2.17
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.68
Resistance 3 (R3) 3.72 3.65 3.64
Resistance 2 (R2) 3.65 3.58 3.64 3.62
Resistance 1 (R1) 3.53 3.54 3.49 3.49 3.61
Pivot Point 3.46 3.46 3.45 3.45 3.46
Support 1 (S1) 3.34 3.39 3.31 3.31 3.19
Support 2 (S2) 3.27 3.35 3.26 3.18
Support 3 (S3) 3.15 3.27 3.16
Support 4 (S4) 3.12